Ardelyx Q2 Revenue Hits Record $118M, But IBSRELA Guidance Cut by $60M
ARDX is trading near its 52-week low of $4.71 (13% below the low).
Summary
Ardelyx posted record Q2 2026 revenue of $118.1M (+31% YoY) but cut its full-year IBSRELA revenue guidance by $60M due to payor access hurdles. The stock trades near its 52-week low, and long-term XPHOZAH guidance was pulled.
Key Events · Earnings and Guidance · ARDX
-
Record Q2 Revenue of $118.1M
Total product revenue grew 31% year-over-year to $118.1 million, with IBSRELA up 33% to $86.2M and XPHOZAH up 27% to $31.9M, marking the largest quarterly revenue in company history.
-
IBSRELA Guidance Cut by $60M
Full-year 2026 IBSRELA revenue guidance was revised to $350–370 million from $410–430 million, a 14% reduction at the midpoint, due to increased payor utilization management processes affecting new patient starts.
-
Long-Term XPHOZAH Guidance Pulled
The company withdrew its long-term XPHOZAH revenue guidance of $750 million, citing evolving market dynamics and growth rates that could reshape the market opportunity.
-
Cash Position Strengthened to $281.8M
Cash, cash equivalents, and investments totaled $281.8 million as of June 30, 2026, up from $264.7 million at year-end 2025, including a $50 million debt drawdown on June 29, 2026.
Analysis · ARDX · Life Sciences
Ardelyx delivered its largest revenue quarter ever at $118.1 million, up 31% year-over-year, driven by strong demand for both IBSRELA and XPHOZAH. However, the company slashed its full-year IBSRELA revenue guidance by $60 million at the midpoint, citing increased payor utilization management hurdles that are slowing new patient starts. The stock is trading near its 52-week low, and the guidance cut—despite record sales—signals that near-term growth headwinds are material. The company also pulled its long-term XPHOZAH outlook and is reassessing the timing of IBSRELA's $1 billion target, adding uncertainty. On the positive side, Ardelyx ended the quarter with $281.8 million in cash and reiterated its path to profitability in 2027, providing a financial cushion as it navigates these challenges.
At the time of this filing, ARDX was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.71 to $8.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.